HSBC Holdings
ABUS icon

HSBC Holdings’s Arbutus Biopharma ABUS Stock Holding History

HSBC Holdings’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,883
Closed -$58.7K – 3004
2025
Q1 		$58.7K Sell
16,883
-111
-0.7% -$370 ﹤0.01% 2887
2024
Q4 		$55.2K Buy
+16,994
New +$62.5K ﹤0.01% 2974
2024
Q3 		– Sell
-13,449
Closed -$40.9K – 2975
2024
Q2 		$40.9K Sell
13,449
-99
-0.7% -$297 ﹤0.01% 2833
2024
Q1 		$35K Buy
+13,548
New +$35.1K ﹤0.01% 2964
2015
Q1 		– Sell
-20,000
Closed -$303K – 2041
2014
Q4 		$303K Sell
20,000
-52,000
-72% -$897K ﹤0.01% 1597
2014
Q3 		$1.53M Sell
72,000
-72,000
-50% -$1.18M ﹤0.01% 1235
2014
Q2 		$1.88M Buy
144,000
+111,400
+342% +$1.58M ﹤0.01% 1155
2014
Q1 		$709K Buy
+32,600
New +$586K ﹤0.01% 1314

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

HSBC Holdings's ABUS Position: Q2 2025 in Review

HSBC Holdings sold out of Arbutus Biopharma (ABUS) in Q2 2025, closing a stake of 16,883 shares — an estimated $58.7K sold.

HSBC Holdings first reported a position in ABUS in Q1 2014 and held it in 8 quarters. The position peaked at $1.88M in Q2 2014. 162 funds tracked by Wall St. Rank hold ABUS as of Q2 2025.

  • HSBC Holdings reported no remaining Arbutus Biopharma position as of Q2 2025 after selling out during the quarter.
  • HSBC Holdings sold 16,883 Arbutus Biopharma shares in Q2 2025, an estimated $58.7K.
  • HSBC Holdings first reported a position in Arbutus Biopharma in Q1 2014 and held it in 8 quarters.
  • HSBC Holdings's Arbutus Biopharma position peaked at $1.88M in Q2 2014.
  • 162 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2025.

Based on HSBC Holdings's 13F filing for Q2 2025, filed 13 Aug 2025.